GSE207376 GSE207377 nutlin-3 0 v 1 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE207376_GSE207377_nutlin-3_0_v_1_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE207376_GSE207377_nutlin-3_0_v_1_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE207376_GSE207377_nutlin-3_0_v_1_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE207376_GSE207377_nutlin-3_0_v_1_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

valyl-tRNA synthetase 1

Gene

small nucleolar RNA host gene 3

Gene

SRC kinase signaling inhibitor 1

Gene

small nucleolar RNA host gene 12

Gene

USP2 antisense RNA 1

Gene

firre intergenic repeating RNA element

Gene

HOXA cluster antisense RNA 3

Gene

5-hydroxytryptamine receptor 7 pseudogene 1

Gene

miR-17-92a-1 cluster host gene

Gene

ANAPC1 pseudogene 2

  • Gene

    valyl-tRNA synthetase 1


  • Gene

    small nucleolar RNA host gene 3


  • Gene

    SRC kinase signaling inhibitor 1


  • Gene

    small nucleolar RNA host gene 12


  • Gene

    USP2 antisense RNA 1


  • Gene

    firre intergenic repeating RNA element


  • Gene

    HOXA cluster antisense RNA 3


  • Gene

    5-hydroxytryptamine receptor 7 pseudogene 1


  • Gene

    miR-17-92a-1 cluster host gene


  • Gene

    ANAPC1 pseudogene 2

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.